Glioblastoma Clinical Trials in Los Angeles, California

9 studies are recruiting for glioblastoma in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

   This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or gliosarcoma that can be removed by surgery (resectable) and that is growing, spr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Locations

   2 in total

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT07089641 on ClinicalTrials.gov

2. Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

   The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the bloo…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Kaiser Permanente, Los Angeles, California

   Locations

   56 in total

   Run by

   CarThera

   See if you can join NCT05902169 on ClinicalTrials.gov

3. Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

   The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, Los Angeles (Data Collection Only), Los Angeles, California

   Locations

   11 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06934889 on ClinicalTrials.gov

4. EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

   This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Gliobla…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Southern California, Los Angeles, California

   Locations

   102 in total

   Run by

   NovoCure GmbH

   See if you can join NCT06556563 on ClinicalTrials.gov

5. A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

   Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnose…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

   Locations

   63 in total

   Run by

   Global Coalition for Adaptive Research

   See if you can join NCT03970447 on ClinicalTrials.gov

6. A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

   RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California

   Locations

   3 in total

   Run by

   RasCal Therapeutics, Inc.

   See if you can join NCT04678648 on ClinicalTrials.gov

7. PH Sensitive MRI Based Resections of Glioblastoma

   Current standard of care therapy and all FDA approved adjuvant therapy for glioblastoma continue to provide less than 12 months of progression free survival (PFS) and less than 24 months of overall survival (OS). There is an extreme need for any novel therapy against glioblastoma that increases pro…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ronald Reagan Medical Center, Los Angeles, California

   Run by

   University of California, Los Angeles

   See if you can join NCT06176066 on ClinicalTrials.gov

8. Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

   This phase III trial is evaluating whether a combination of three advanced magnetic resonance imaging (MRI) techniques, including chemical exchange saturation transfer (CEST) MRI, diffusion-relaxation correlation spectrum imaging (DR-CSI), and ferumoxytol-enhanced magnetic resonance imaging (Fe-MRI…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT07461948 on ClinicalTrials.gov

9. Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma

   This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable). Malignant gliomas are the second leading cause of cancer mortality in people under the age of 35 in the Uni…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT06090903 on ClinicalTrials.gov